Page 178 - Genentech News Today

PREVIOUSLY:

Sleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition.

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to have received notification...

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

‒ Vabysmo data suggest rapid and robust drying of retinal fluid in patients with wet age-related macular degeneration and diabetic macular edema – ‒ Real-wo ...

Vabysmo data suggest rapid and robust drying of retinal fluid in patients with neovascular or 'wet' age-related macular degeneration and diabetic macular edema Real-world studies of Vabysmo demonstrate

Genentech was the worlds first biotech company, with breakthrough treatments for everything from cancer to multiple sclerosis. But if not for Fred Frank —…

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed. However, nearly one-third of patients for whom CAR-T had been recommended did not receive the treatment, findings from a poll of health care professionals presented at National Comprehensive

As part of a $1 billion deal forged in 2020, Biogen has exercised the option to license a treatment candidate for Alzheimer’s disease developed by the US biotech company Denali Therapeutics. The engineered antibody drug is designed to cross into the brain and break down harmful plaques better than approved antibodies can.

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that it will highlight new data for its approved and investigational medicines in...